

Odile Beyne-Rauzy

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/7334625/publications.pdf>

Version: 2024-02-01

94
papers

5,198
citations

117625

34
h-index

85541

71
g-index

97
all docs

97
docs citations

97
times ranked

5269
citing authors

#	ARTICLE	IF	CITATIONS
1	Small Private Online Course in Teaching Oncologyâ€”Feedback After 1Â”Year: What Lessons?. Journal of Cancer Education, 2021, 36, 65-71.	1.3	9
2	Impact of red blood cell transfusion dose density on progression-free survival in patients with lower-risk myelodysplastic syndromes. Haematologica, 2020, 105, 632-639.	3.5	35
3	Luspatercept in Patients with Lower-Risk Myelodysplastic Syndromes. New England Journal of Medicine, 2020, 382, 140-151.	27.0	335
4	A phase II study of guadecitabine in higher-risk myelodysplastic syndrome and low blast count acute myeloid leukemia after azacitidine failure. Haematologica, 2019, 104, 1565-1571.	3.5	39
5	APR-246 Combined with Azacitidine (AZA) in TP53 Mutated Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML). a Phase 2 Study By the Groupe Francophone Des MyÃ©lodysplasies (GFM). Blood, 2019, 134, 677-677.	1.4	62
6	Azacitidine improves outcome in higherâ€”risk <scp>MDS</scp> patients with chromosome 7 abnormalities: a retrospective comparison of <scp>GESMD</scp> and <scp>GFM</scp> registries. British Journal of Haematology, 2018, 181, 350-359.	2.5	11
7	Sotatercept with long-term extension for the treatment of anaemia in patients with lower-risk myelodysplastic syndromes: a phase 2, dose-ranging trial. Lancet Haematology, the, 2018, 5, e63-e72.	4.6	95
8	Prognostic impact of a suboptimal number of analyzed metaphases in normal karyotype lower-risk MDS. Leukemia Research, 2018, 67, 21-26.	0.8	4
9	Pretreatment with standardâ€”dose intravenous methylprednisolone does not improve outcomes in newly diagnosed immune thrombocytopenia (<scp>ITP</scp>). European Journal of Haematology, 2018, 100, 412-418.	2.2	2
10	Prospective evaluation of the effect of deferasirox on hematologic response in transfusionâ€”dependent patients with lowâ€”risk <scp>MDS</scp> and iron overload. European Journal of Haematology, 2018, 101, 165-173.	2.2	7
11	Re: Severe Primary Autoimmune Thrombocytopenia (<scp>ITP</scp>) in Pregnancy: a national cohort study Primary immune thrombocytopenia management during pregnancy. A French study. BJOG: an International Journal of Obstetrics and Gynaecology, 2018, 125, 629-630.	2.3	3
12	Immune checkpoint inhibitor-related acral vasculitis. , 2018, 6, 120.		32
13	The Medalist Trial: Results of a Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Luspatercept to Treat Anemia in Patients with Very Low-, Low-, or Intermediate-Risk Myelodysplastic Syndromes (MDS) with Ring Sideroblasts (RS) Who Require Red Blood Cell (RBC) Transfusions. Blood, 2018, 132, 1-1.	1.4	57
14	A Randomized Phase II Study of Azacitidine (AZA) Alone or with Lenalidomide (LEN), Valproic Acid (VPA) or Idarubicin (IDA) in Higher-Risk MDS: Gfm's 'pick a Winner' Trial. Blood, 2018, 132, 467-467.	1.4	9
15	The Impact of a Small Private Online Course as a New Approach to Teaching Oncology: Development and Evaluation. JMIR Medical Education, 2018, 4, e6.	2.6	15
16	Newly diagnosed immune thrombocytopenia adults: Clinical epidemiology, exposure to treatments, and evolution. Results of the CARMEN multicenter prospective cohort. American Journal of Hematology, 2017, 92, 493-500.	4.1	67
17	Clinical characteristics and outcomes according to age in lenalidomide-treated patients with RBC transfusion-dependent lower-risk MDS and del(5q). Journal of Hematology and Oncology, 2017, 10, 131.	17.0	8
18	Outcome of Lower-Risk Patients With Myelodysplastic Syndromes Without 5q Deletion After Failure of Erythropoiesis-Stimulating Agents. Journal of Clinical Oncology, 2017, 35, 1591-1597.	1.6	79

#	ARTICLE	IF	CITATIONS
19	Validation of immune thrombocytopenia diagnosis code in the French hospital electronic database. <i>European Journal of Internal Medicine</i> , 2016, 32, e21-e22.	2.2	11
20	Are somatic mutations predictive of response to erythropoiesis stimulating agents in lower risk myelodysplastic syndromes?. <i>Haematologica</i> , 2016, 101, e280-e283.	3.5	41
21	A randomized phase II trial of azacitidine +/- epoetin- \hat{A} in lower-risk myelodysplastic syndromes resistant to erythropoietic stimulating agents. <i>Haematologica</i> , 2016, 101, 918-925.	3.5	55
22	Myelodysplastic syndromes with single neutropenia or thrombocytopenia are rarely refractory cytopenias with unilineage dysplasia by World Health Organization 2008 criteria and have favourable prognosis. <i>British Journal of Haematology</i> , 2016, 175, 975-979.	2.5	15
23	Effect of lenalidomide treatment on clonal architecture of myelodysplastic syndromes without 5q deletion. <i>Blood</i> , 2016, 127, 749-760.	1.4	36
24	Prospective Evaluation of the Effect of Deferasirox on Hematologic Response in Transfusion-Dependent Patients with Low-Risk MDS and Iron Overload: The Rythmex Study. <i>Blood</i> , 2016, 128, 2008-2008.	1.4	4
25	Impact of Treatment with Iron Chelators in Lower-Risk MDS Patients Participating in the European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2016, 128, 3186-3186.	1.4	14
26	Results of a Phase II Study of Guadecitabine (SGI-110) in Higher Risk MDS, CMML or Low Blast Count AML Patients Refractory to or Relapsing after Azacitidine (AZA) Treatment. <i>Blood</i> , 2016, 128, 347-347.	1.4	10
27	Interest in Initiating Corticosteroids By Intravenous Methylprednisolone at Standard Dose in Newly Diagnosed Immune Thrombocytopenia Adults: Results of the Prospective Carmen Registry. <i>Blood</i> , 2016, 128, 3736-3736.	1.4	0
28	Positivity Rates of Tests Used at Immune Thrombocytopenia Diagnosis to Detect Associated Diseases. a Prospective Multicenter Cohort Study of 218 Patients. <i>Blood</i> , 2016, 128, 1367-1367.	1.4	0
29	Validation of the revised international prognostic scoring system (<sc>IPSS</sc>â€) in patients with lowerâ€risk myelodysplastic syndromes: a report from the prospective European LeukaemiaNet <sc>MDS</sc> (<sc>EUMDS</sc>) registry. <i>British Journal of Haematology</i> , 2015, 170, 372-383.	2.5	72
30	Ribavirin for Chronic Hepatitis Prevention among Patients with Hematologic Malignancies. <i>Emerging Infectious Diseases</i> , 2015, 21, 1466-1469.	4.3	41
31	Prognostic value of self-reported fatigue on overall survival in patients with myelodysplastic syndromes: a multicentre, prospective, observational, cohort study. <i>Lancet Oncology</i> , The, 2015, 16, 1506-1514.	10.7	76
32	Prevalence, severity and correlates of fatigue in newly diagnosed patients with myelodysplastic syndromes. <i>British Journal of Haematology</i> , 2015, 168, 361-370.	2.5	59
33	Clinical Epidemiology and First-Line Treatment in Immune Thrombocytopenia Adults. Results of the Carmen Prospective Cohort. <i>Blood</i> , 2015, 126, 3473-3473.	1.4	3
34	Eltrombopag for the Treatment of Thrombocytopenia of Low and Intermediate-1 IPSS Risk Myelodysplastic Syndromes: Interim Results on Efficacy, Safety and Quality of Life of an International, Multicenter Prospective, Randomized, Trial. <i>Blood</i> , 2015, 126, 91-91.	1.4	7
35	Markers of Oxidative Stress Do Not Correlate with Labile Plasma Iron Blood in Patients with Myelodysplastic Syndromes. <i>Blood</i> , 2015, 126, 2149-2149.	1.4	0
36	Outcome of Lower Risk Non Del 5q MDS after Failure of Erythropoiesis Stimulating Agents (ESA), and Impact of Post-ESA Treatment on Survival: A Retrospective European Study. <i>Blood</i> , 2015, 126, 1665-1665.	1.4	1

#	ARTICLE	IF	CITATIONS
37	Prognostic Impact of Transfusions Intensity on Survival and Development of Thrombocytopenia in Newly Diagnosed Lower-Risk MDS Patients Participating in the European Leukemianet EU-MDS Registry. <i>Blood</i> , 2015, 126, 1677-1677.	1.4	0
38	Incidence of Adverse Drug Reactions Related to Immune Thrombocytopenia Drugs. A Prospective Cohort Study. <i>Blood</i> , 2015, 126, 1056-1056.	1.4	0
39	Intensive chemotherapy, azacitidine, or supportive care in older acute myeloid leukemia patients: An analysis from a regional healthcare network. <i>American Journal of Hematology</i> , 2014, 89, E244-52.	4.1	59
40	Outcomes in RBC transfusion-dependent patients with low-intermediate-1 risk myelodysplastic syndromes with isolated deletion 5q treated with lenalidomide: a subset analysis from the MDS-004 study. <i>European Journal of Haematology</i> , 2014, 93, 429-438.	2.2	32
41	Combination of vorinostat and low dose cytarabine for patients with azacitidine-refractory/relapsed high risk myelodysplastic syndromes. <i>Leukemia Research</i> , 2014, 38, 29-33.	0.8	16
42	A phase I/II trial of Erlotinib in higher risk myelodysplastic syndromes and acute myeloid leukemia after azacitidine failure. <i>Leukemia Research</i> , 2014, 38, 1430-1434.	0.8	16
43	Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison. <i>Blood</i> , 2014, 124, 3193-3193.	1.4	3
44	An Open-Label, Phase 2, Dose-Finding Study of Sotatercept (ACE-011) in Patients with Low or Intermediate-1 (Int-1)-Risk Myelodysplastic Syndromes (MDS) or Non-Proliferative Chronic Myelomonocytic Leukemia (CMML) and Anemia Requiring Transfusion. <i>Blood</i> , 2014, 124, 3251-3251.	1.4	23
45	NPM1 Expression Level and a CRBN Polymorphism Are Able to Predict the Rate of Response to Lenalidomide in Non Del(5q) Lower Risk MDS Patients Resistant to Erythropoiesis-Stimulating Agents: The GFM Experience. <i>Blood</i> , 2014, 124, 533-533.	1.4	1
46	Prognostic Score Including Gene Mutations in Chronic Myelomonocytic Leukemia. <i>Journal of Clinical Oncology</i> , 2013, 31, 2428-2436.	1.6	462
47	Cardiac iron overload assessed by T2* magnetic resonance imaging and cardiac function in regularly transfused myelodysplastic syndrome patients. <i>British Journal of Haematology</i> , 2013, 162, 413-415.	2.5	29
48	Can the revised IPSS predict response to erythropoietic-stimulating agents in patients with classical IPSS low or intermediate-1 MDS?. <i>Blood</i> , 2013, 122, 2286-2288.	1.4	67
49	Validation Of The Revised International Prognostic Scoring System (IPSS-R) In 1000 Newly Diagnosed MDS Patients With Low- and Intermediate-1 Risk MDS In The European Leukemianet MDS (EUMDS) Registry. <i>Blood</i> , 2013, 122, 2770-2770.	1.4	3
50	The Revised IPSS (IPSS-R) Predicts Response To Erythropoietic Stimulating agents (ESA) In Pts With Classical IPSS Low Or Intermediate-1 (int 1)- MDS: A Joint Retrospective Study Of The GFM, Düsseldorf Registry and Fism. <i>Blood</i> , 2013, 122, 2761-2761.	1.4	1
51	Outcomes In RBC Transfusion-Dependent Patients (Pts) With Low-/Intermediate (Int)-1-Risk Myelodysplastic Syndromes (MDS) With Isolated Deletion 5q Treated With Lenalidomide (LEN): A Subset Analysis From The MDS-004 Study. <i>Blood</i> , 2013, 122, 2753-2753.	1.4	0
52	Mutations affecting mRNA splicing define distinct clinical phenotypes and correlate with patient outcome in myelodysplastic syndromes. <i>Blood</i> , 2012, 119, 3211-3218.	1.4	220
53	Prognostic Factors of Response to Erythropoiesis Stimulating Agents (ESA) Treatment in Non RBC Transfusion Dependent Lower Risk MDS. Preliminary Results of a French and Italian Study (on behalf of the European Leukemianet MDS (EUMDS) Registry). <i>Blood</i> , 2012, 120, 3811-3811.	1.4	1
54	Comprehensive Genetic Screening of Chronic Myelomonocytic Leukemias (CMML). <i>Blood</i> , 2012, 120, 3811-3811.	1.4	1

#	ARTICLE	IF	CITATIONS
55	Is Azacitidine (AZA) Really Effective in High Risk MDS Patients with Chromosome 7 Abnormalities (Abn) Tj ETQq1 1 0,784314rgBT /Ower	1.4	4
56	BCOR Mutations Represent an Independent Factor of Poor Prognosis in Myelodysplastic Syndromes. Blood, 2012, 120, 1697-1697.	1.4	0
57	A phase I /II Trial of Erlotinib in Higher Risk MDS After Azacitidine (AZA) Failure. Blood, 2012, 120, 1719-1719.	1.4	0
58	A randomized phase 3 study of lenalidomide versus placebo in RBC transfusion-dependent patients with Low-/Intermediate-1-risk myelodysplastic syndromes with del5q. Blood, 2011, 118, 3765-3776.	1.4	424
59	Prognostic factors for response and overall survival in 282 patients with higher-risk myelodysplastic syndromes treated with azacitidine. Blood, 2011, 117, 403-411.	1.4	348
60	Treatment by Lenalidomide in lower risk myelodysplastic syndrome with 5q deletionâ€”The GFM experience. Leukemia Research, 2011, 35, 1444-1448.	0.8	36
61	Characteristics and outcome of myelodysplastic syndromes (MDS) with isolated 20q deletion: A report on 62 cases. Leukemia Research, 2011, 35, 863-867.	0.8	44
62	Home Azacitidine Administration in High Risk Myelodysplastic Syndromes: Favorable Results of a Pilot Study in 48 Patients. Blood, 2011, 118, 1719-1719.	1.4	1
63	Transfusion-Dependency Is the Most Important Prognostic Factor for Survival in 1000 Newly Diagnosed MDS Patients with Low- and Intermediate-1 Risk MDS in the European LeukemiaNet MDS Registry. Blood, 2011, 118, 2775-2775.	1.4	20
64	Daily practice management of myelodysplastic syndromes in France: data from 907 patients in a one-week cross-sectional study by the Groupe Francophone des Myelodysplasies. Haematologica, 2010, 95, 892-899.	3.5	18
65	Does iron chelation therapy improve survival in regularly transfused lower risk MDS patients? A multicenter study by the GFM. Leukemia Research, 2010, 34, 864-870.	0.8	183
66	Early introduction of ESA in low risk MDS patients may delay the need for RBC transfusion: A retrospective analysis on 112 patients. Leukemia Research, 2010, 34, 1430-1436.	0.8	60
67	Prolonged survival with improved tolerability in higherâ€”risk myelodysplastic syndromes: azacitidine compared with low dose araâ€”. British Journal of Haematology, 2010, 149, 244-249.	2.5	75
68	Should Immunosuppressive Therapy (IST) Be Used More Often In Lower Risk MDS?. Blood, 2010, 116, 1868-1868.	1.4	1
69	Interim Results of A Randomized Phase II Trial of Azacitidine (AZA) +/âˆ” Epo In Lower Risk Myelodysplastic Syndrome (MDS) Resistant to An Erythropoietic Stimulating Agent (ESA) Alone. Blood, 2010, 116, 1880-1880.	1.4	6
70	Prolonged Survival without Complete Remission (CR) In AML Patients (Pts) Treated with Azacitidine (AZA). Blood, 2010, 116, 2183-2183.	1.4	13
71	FAS Gene Expression Is Epigenetically Regulated and Predicts the Responsiveness to Azacitidine In High-Risk Myelodysplastic Syndromes. Blood, 2010, 116, 232-232.	1.4	3
72	Disease-Management of Low- and Intermediate-1 Risk Myelodysplastic Syndromes: Report on 800 Newly Diagnosed MDS Patients From the European LeukemiaNet MDS Registry. Blood, 2010, 116, 2917-2917.	1.4	5

#	ARTICLE	IF	CITATIONS
73	Health-Related Quality of Life In Newly Diagnosed Low Risk and Intermediate-1 Risk MDS: Report on the First 683 Patients From the European LeukemiaNet Registry. <i>Blood</i> , 2010, 116, 3999-3999.	1.4	1
74	Long-Term Outcome of Anemic Non Del 5q Lower-Risk MDS Refractory to or Relapsing After Erythropoiesis Stimulating Agents (ESAs). <i>Blood</i> , 2010, 116, 442-442.	1.4	1
75	Prognostic Impact of JAK2V617F Mutation In MDS: a Matched Case Control Study. <i>Blood</i> , 2010, 116, 440-440.	1.4	0
76	Prognostic Factors of Long-Term Outcomes In Low- or Int-1-Risk MDS with del5q Treated with Lenalidomide (LEN): Results From a Randomized Phase 3 Trial (MDS-004). <i>Blood</i> , 2010, 116, 4027-4027.	1.4	0
77	Correlation Between serum ferritin Level at diagnosis and Survival In Lower Risk, Non-Transfusion Dependent, MDS Patients.A Report by the Groupe Francophone Des Myelodysplasies (GFM). <i>Blood</i> , 2010, 116, 2916-2916.	1.4	0
78	A Prognostic Score for Overall Survival (OS) with Azacitidine (AZA) In Higher Risk MDS Based on 282 Patients (pts), and Validated In 175 Pts From the AZA 001 Trial. <i>Blood</i> , 2010, 116, 3996-3996.	1.4	0
79	TET2 gene mutation is a frequent and adverse event in chronic myelomonocytic leukemia. <i>Haematologica</i> , 2009, 94, 1676-1681.	3.5	234
80	Efficacy and safety of lenalidomide in intermediate-2 or high-risk myelodysplastic syndromes with 5q deletion: results of a phase 2 study. <i>Blood</i> , 2009, 113, 3947-3952.	1.4	158
81	TET2 mutation is an independent favorable prognostic factor in myelodysplastic syndromes (MDSs). <i>Blood</i> , 2009, 114, 3285-3291.	1.4	264
82	Treatment of Lower Risk MDS with Del 5q with Lenalidomide (LEN): Results of the French ATU Program.. <i>Blood</i> , 2009, 114, 2764-2764.	1.4	20
83	Predictive factors of response and survival in myelodysplastic syndrome treated with erythropoietin and G-CSF: the GFM experience. <i>Blood</i> , 2008, 111, 574-582.	1.4	295
84	The human spleen is a major reservoir for long-lived vaccinia virus-specific memory B cells. <i>Blood</i> , 2008, 111, 4653-4659.	1.4	145
85	Myelodysplastic Syndrome (MDS) in France: Results of a One-Week Cross-Sectional Survey on Daily Practice Management in 919 Patients by the GFM. <i>Blood</i> , 2008, 112, 2672-2672.	1.4	2
86	Fas-Dependent Apoptosis in Early MDS Erythroid Precursors Involves Endoplasmic Reticulum.. <i>Blood</i> , 2007, 110, 3346-3346.	1.4	0
87	Both the Endoplasmic Reticulum and the Mitochondria Are Involved in Apoptosis of Erythroid Precursors in Low Grade Myelodysplastic Syndromes.. <i>Blood</i> , 2006, 108, 2638-2638.	1.4	0
88	Antileukemic activity of rapamycin in acute myeloid leukemia. <i>Blood</i> , 2005, 105, 2527-2534.	1.4	280
89	Tumor necrosis factor- α inhibits hTERT gene expression in human myeloid normal and leukemic cells. <i>Blood</i> , 2005, 106, 3200-3205.	1.4	41
90	A non-randomised dose-escalating phase II study of thalidomide for the treatment of patients with low-risk myelodysplastic syndromes: the Thal-SMD-2000 trial of the Groupe Francais des Myelodysplasies. <i>British Journal of Haematology</i> , 2005, 131, 609-618.	2.5	44

#	ARTICLE	IF	CITATIONS
91	Anti-PCNA antibodies: prevalence and predictive value. <i>Joint Bone Spine</i> , 2005, 72, 432-435.	1.6	19
92	Expression of Focal Adhesion Kinase in Acute Myeloid Leukemia Is Associated with Enhanced Blast Migration, Increased Cellularity, and Poor Prognosis. <i>Cancer Research</i> , 2004, 64, 3191-3197.	0.9	140
93	Tumor necrosis factor alpha induces senescence and chromosomal instability in human leukemic cells. <i>Oncogene</i> , 2004, 23, 7507-7516.	5.9	63
94	Activity of Rapamycin in Patients with Relapsed, Refractory or Poor-Risk Acute Myeloid Leukemia.. <i>Blood</i> , 2004, 104, 1791-1791.	1.4	0